TD Cowen Maintains Hold on Myriad Genetics, Lowers Price Target to $4
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $6 to $4.
TD Cowen analyst Kyle Boucher maintains Myriad Genetics (NASDAQ:MYGN) with a Hold and lowers the price target from $6 to $4.